A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.
Also called NCT06362759
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 143 participants
- Sponsor
- Tourmaline Bio, Inc., a Novartis Company
- Registry
-
NCT06362759
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT06362759. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-15 (actual); primary completion 2025-03-06 (actual). Results posted on 2026-08-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
- Acronym
- TRANQUILITY
- Condition
- Chronic Kidney Diseases
- Condition
- Chronic Kidney Insufficiency
- Condition
- Chronic Renal Diseases
- Condition
- Chronic Renal Insufficiency
- Condition
- Kidney Insufficiency, Chronic
- Condition
- C-Reactive Protein
- Condition
- High Sensitivity C-Reactive Protein
- Condition
- Hs-CRP
- Condition
- hsCRP
- Intervention (Drug)
- TOUR006 - 50 MG
- Intervention (Drug)
- TOUR006 - 25 MG
- Intervention (Drug)
- TOUR006 - 15 MG
- Intervention (Other)
- Placebo
- Lead sponsor
- Tourmaline Bio, Inc., a Novartis Company
Record details
- Record id
cardio:ct-nct06362759- Content hash
a66cc1cfe1f2b1e85b23ade5bf0c449348f0e4da30727c74aa45a0b35d5c6c3c